Clinical Trials
11 trialsNCT02812420 2026-03-05
Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT06824363 2026-01-30
ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu
University of California, Irvine
Phase EARLY_PHASE1 Not yet recruiting
NCT03215095 2025-07-17
RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT03618654 2025-05-15
Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma
Thomas Jefferson University
Phase EARLY_PHASE1 Completed
NCT02827838 2025-03-17
Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer
Wake Forest University Health Sciences
Phase EARLY_PHASE1 Terminated
NCT03132467 2024-06-05
Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT03818776 2024-02-15
Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT04223648 2021-11-22
Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma
Yale University
Phase EARLY_PHASE1 Withdrawn
NCT04088032 2020-07-16
Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
Stony Brook University
Phase EARLY_PHASE1 Withdrawn
NCT02802098 2020-06-19
Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase EARLY_PHASE1 Completed
NCT03235869 2018-03-15
Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma
University of Michigan Rogel Cancer Center
Phase EARLY_PHASE1 Withdrawn